Persevere Therapeutics Launches With Seed Financing to Advance Novel Oncology Drug Into Mid-Stage Clinical Trials
Persevere Therapeutics, a clinical-stage oncology biotechnology company focused on advancing novel cancer therapies, has emerged from stealth mode and announced the first close of its seed financing round as it prepares to advance its lead drug candidate into a Phase 1b/2a clinical trial. The Chesterbrook, Pennsylvania-based company launched publicly in March 2026, unveiling plans to develop misetionamide, a first-in-class small-molecule therapy targeting difficult-to-treat cancers.
The newly formed company said it has acquired the clinical-stage program and related assets for misetionamide, also known as GP-2250, from Geistlich Pharma AG. The transaction provides Persevere Therapeutics with a Phase 1b/2a-ready asset that has already undergone extensive preclinical and clinical development. The company announced that proceeds from its seed financing will be used to complete a proof-of-concept Phase 1b/2a clinical study evaluating misetionamide in patients with platinum-resistant ovarian cancer, an area where treatment options remain limited and outcomes are often poor.
Founded in 2025, Persevere Therapeutics is led by founder and chief executive officer Greg Bosch. The company’s mission centers on improving clinical outcomes for cancer patients through the development of therapies with novel mechanisms of action. According to the company, misetionamide is a dual inhibitor of c-MYC and NFκB, two oncogenic transcription factors that play important roles in tumor growth, metabolism, proliferation, and survival. By targeting these pathways simultaneously, the drug candidate is designed to disrupt cancer cell metabolism and inhibit tumor progression.
Persevere’s launch follows a period of quiet development during which the company assembled its scientific and operational strategy. The company noted that misetionamide enters its pipeline with a substantial body of supporting research, including extensive preclinical studies, regulatory work conducted under investigational new drug applications, and a completed Phase 1 clinical trial involving 56 cancer patients. Those earlier efforts demonstrated an encouraging safety profile and clinical activity, providing the foundation for the next stage of development.
The seed financing marks a critical step in moving the program forward. While Persevere has not publicly disclosed the identities of investors participating in the seed round, the company confirmed that it has completed an initial tranche of financing and remains engaged with additional prospective investors regarding the remaining allocation. Public reports indicate that the company raised approximately $1.57 million in its first disclosed seed financing close while continuing efforts toward a larger fundraising target.
The financing arrives at a time when investor interest in oncology innovation remains strong despite a challenging biotechnology funding environment in recent years. Companies developing differentiated therapies for cancers with significant unmet medical needs continue to attract attention from investors seeking opportunities in clinical-stage drug development. Persevere believes misetionamide’s novel mechanism and existing clinical foundation position it well within this landscape.
In addition to ovarian cancer, the company sees broader potential for the therapy across multiple tumor types. Persevere has highlighted pancreatic cancer among its initial strategic areas of focus and has noted that preclinical and clinical research has explored the drug’s activity in other cancers, including melanoma, breast cancer, colorectal cancer, and squamous cell carcinoma. The company plans to prioritize indications where significant unmet need exists and where the mechanism of action may offer meaningful therapeutic benefit.
The acquisition of the misetionamide program from Geistlich Pharma AG provides Persevere with intellectual property, clinical data, and development assets that management believes can accelerate the pathway toward future clinical milestones. Company executives have emphasized that years of prior investment and scientific work have reduced some of the early-stage development risks often associated with newly launched biotechnology ventures.
With seed financing secured and a clinical-stage asset in hand, Persevere Therapeutics is now focused on advancing its upcoming Phase 1b/2a study and generating data that could support further development. As the company continues discussions with prospective investors and expands its clinical efforts, the progress of misetionamide will be closely watched by stakeholders seeking new treatment options for patients facing some of the most challenging forms of cancer.
